Press release
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
− Achieved Second Quarter 2021 Combined Net Product Revenues of $161 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® – − Advanced Vutrisiran with New Drug
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n− Achieved Second Quarter 2021 Combined Net Product Revenues of $161 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® –\n\n− Advanced Vutrisiran with New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis (hATTR-PN); Received FDA Acceptance of NDA with Prescription Drug User Fee Act (PDUFA) Date Set for April 14, 2022 –\n\n– Completed Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy (ATTR-CM) –\n\n– Initiated KARDIA Phase 2 Program with Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension –\n\n– Increased 2021 Guidance Range for Combined Net Product Revenues from $610-$660 Million to $640-$665 Million –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2021 and reviewed recent business highlights.\n\n“Our commercial performance in the second quarter continued to demonstrate steady and continued growth across our three wholly owned marketed products. The second quarter also marked significant progress for our TTR franchise overall, including NDA submission and acceptance for vutrisiran based on positive HELIOS-A results, initiation of a biannual dosing study for vutrisiran, completion of enrollment in the APOLLO-B Phase 3 trial and imminent enrollment completion for HELIOS-B, and introduction of ALN-TTRsc04 for a potential annual dosing regimen. Together, these efforts highlight our commitment to ATTR amyloidosis for years to come,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “With sights set on our ‘Alnylam P5x25’ five-year vision announced earlier this year, we believe we are well positioned and on our way to achieving these ambitious goals. With this strategy we intend to deliver transformative medicines for rare and prevalent diseases to patients around the world, advancing a robust and high-yielding clinical pipeline of first and/or best-in-class product candidates stemming from our organic product engine, while delivering exceptional financial performance.”\n\n\nSecond Quarter 2021 and Recent Significant Corporate Highlights\n\nCommercial Performance\n\nO...